According to the report, Medicare Part D drugs that demonstrated the lowest annual cost increases offered higher average rebates than drugs with the highest annual cost increases.
While the Trump administration is considering a proposal from HHS to overhaul safe harbor protections for rebates given by drug makers to health plans and pharmacy benefit managers as a way to bring down high drug prices, a new report prepared for America’s Health Insurance Plans (AHIP) suggests that much-maligned rebates are not to blame for increases in drug prices.
AHIP engaged consulting company Milliman to examine Medicare Part D drug prices and manufacturer rebates to help the organization prepare its comments in response to the administration’s blueprint to lower the price of drugs for American patients. Milliman used publicly available Part D drug spending and utilization data from 2013 to 2016, combined with 2016 data from contributing health plans on rebates.
According to the report, rebates are typically offered only for brand-name drugs; 81% of all of the Part D drugs analyzed offered no rebates. Furthermore, 64% of brand-name drugs did not offer rebates, and non-specialty drugs—rather than pricier specialty products—had the highest rebates when measured as a percentage of gross drug costs.
Of the 706 branded products analyzed, representing 95% of brand drug spending, only 36% had more than a nominal manufacturer rebate (rebates representing more than 1% of the drug’s gross cost), and only 27% offered significant rebates (representing 12% or more of the drug’s gross cost).
Products that face direct brand competition had a higher proportion of drugs that offered rebates (as well as a higher average rebate as a percentage of gross costs), while those in protected classes had the lowest proportion of rebates (and the lowest average rebate as a percentage of gross costs). Those products that faced direct competition offered rebates that totaled approximately 39% of gross costs, while products that were in protected classes offered rebates that totaled just 14% of the same.
Notably, while drugs with rebates offered in 2016 had higher price trends than did drugs without rebates, the average annual gross cost per Medicare beneficiary has increased more quickly for drugs that offered no rebates. Products that demonstrated the lowest annual cost increases offered higher average rebates than drugs with the highest annual cost increases.
The report’s findings suggest that addressing rebates alone will not reduce drug prices; while Milliman and AHIP’s report did not offer direct proposals as to how to address the problem of high drug prices outside of targeting rebates, competition, the findings suggest, may be the key.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.